Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › PCVX

Vaxcyte

PCVX Lead: Phase 3 4 Biotech Distilled articles ↓
Infectious Disease Protein

Most recent annual filing: 2026-02-24

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. VAX-31 infant Ph2 topline1H 2027VAX-31 infant Ph2 topline, 1H 2027, material
  2. VAX-A1 Ph1 topline2H 2027VAX-A1 Ph1 topline, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

XpressCF · Sutro Biopharma

Cell-free protein synthesis platform exclusively licensed from Sutro Biopharma; used to produce difficult-to-make proteins and antigens for high-fidelity vaccine development, focused on bacterial disease prevention including pneumococcal, Group A Strep, and Shigella vaccines.

Cell-Free Protein Synthesis Platform

Cell-free platform technology enabling superior site-specific conjugation chemistry, production of difficult-to-make protein antigens, and broad-spectrum vaccine development beyond reach of conventional methods; focus areas include pneumococcal and Group A Streptococcal vaccines.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.